Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned a consensus rating of “Moderate Buy” from the seven brokerages that are covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $22.60.

Several research firms recently issued reports on TBPH. BTIG Research decreased their price target on Theravance Biopharma from $40.00 to $21.00 and set a “buy” rating on the stock in a report on Tuesday. Oppenheimer downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday. HC Wainwright raised their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday. Wall Street Zen cut shares of Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, B. Riley Financial reissued a “neutral” rating and set a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday.

Theravance Biopharma Stock Performance

NASDAQ TBPH opened at $13.58 on Friday. The stock has a fifty day moving average of $19.06 and a 200-day moving average of $16.83. The stock has a market capitalization of $688.10 million, a P/E ratio of 23.82 and a beta of 0.17. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $21.03.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new position in shares of Theravance Biopharma in the 1st quarter worth $101,000. Jane Street Group LLC lifted its stake in Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock valued at $1,258,000 after buying an additional 88,540 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in Theravance Biopharma in the second quarter valued at about $452,000. Los Angeles Capital Management LLC bought a new position in Theravance Biopharma during the second quarter worth about $219,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Theravance Biopharma during the second quarter worth about $624,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.